Vertex Pharmaceuticals Incorporated Press Releases

Get VRTX Alerts
*Delayed - data as of Sep. 16, 2014  -  Find a broker to begin trading VRTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    VRTX After Hours
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By

Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
9/8/2014 9:00:00 AM - Business Wire

Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
9/2/2014 4:01:00 PM - Business Wire

Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
7/31/2014 4:18:00 PM - Business Wire

Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
7/29/2014 4:01:00 PM - Business Wire

Vertex to Announce Second Quarter 2014 Financial Results on July 29
7/14/2014 4:01:00 PM - Business Wire

Vertex Announces Retirement of Peter Mueller, Ph.D.
7/10/2014 8:00:00 AM - Business Wire

Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation
6/30/2014 4:05:00 PM - Business Wire

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vertex Pharmaceuticals Inc. To Contact The Firm
6/27/2014 10:17:00 PM - PR Newswire

Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
6/27/2014 7:14:00 AM - Business Wire

Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
6/27/2014 7:00:00 AM - PR Newswire

Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
6/24/2014 7:00:00 AM - Business Wire